Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Harmony Biosciences Holdings, which markets a therapy for adult narcolepsy in the US, raised $128 million by offering 5.3 million shares above the proposed range at $24. The company originally planned to offer 4.7 million shares at a range of $20 to $23. At IPO,...read more
Updated Monday, 8/17.
Three biotechs, a medical imaging company, and three SPACs are scheduled to go public in the week ahead. While the annual summer slowdown is setting in, the IPO market is still in the midst of its most active August since...read more
Harmony Biosciences Holdings, a commercial stage biotech developing therapies for narcolepsy and other CNS disorders, announced terms for its IPO on Tuesday. The Plymouth Meeting, PA-based company plans to raise $100 million by offering 4.7 million shares...read more
US IPO Weekly Recap: Biotechs and SPACs ride the summer wave in a 4 IPO week
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Narcolepsy pharmaceutical Harmony Biosciences prices upsized IPO above the range at $24
Harmony Biosciences Holdings, which markets a therapy for adult narcolepsy in the US, raised $128 million by offering 5.3 million shares above the proposed range at $24. The company originally planned to offer 4.7 million shares at a range of $20 to $23. At IPO,...read more
US IPO Week Ahead: The IPO market's summer slowdown approaches in a 4 IPO week
Updated Monday, 8/17. Three biotechs, a medical imaging company, and three SPACs are scheduled to go public in the week ahead. While the annual summer slowdown is setting in, the IPO market is still in the midst of its most active August since...read more
CNS disorder biotech Harmony Biosciences sets terms for $100 million IPO
Harmony Biosciences Holdings, a commercial stage biotech developing therapies for narcolepsy and other CNS disorders, announced terms for its IPO on Tuesday. The Plymouth Meeting, PA-based company plans to raise $100 million by offering 4.7 million shares...read more